A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy

Cancer: Principles and Practice of Oncology.

Annals of Internal Medicine · 1991 · 8.5K citations

Medicine, Oncology, Oncology Nursing +10

Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis

Michel Marty, P Pouillart, Jean Pierre Droz et al. · New England Journal of Medicine · 1990 · 411 citations

Medicine, Pharmacology, Pharmacotherapy +17

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

Rudolph M. Navari, Rick R. Reinhardt, Richard J. Gralla et al. · New England Journal of Medicine · 1999 · 371 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Quality of life consequences of chemotherapy-induced emesis

Celeste Lindley, Jan D. Hirsch, Casey O'Neill et al. · Quality of Life Research · 1992 · 257 citations

Medicine, Oncology, Pharmacology +14

Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs.

A. Gafni · PubMed · 1991 · 190 citations

Public Affairs, Health Policy, Public Policy +14